Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Neupert
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter Neupert

Peter Neupert

Board Member, Adaptive Biotechnologies

CrunchbaseLinkedIn

Peter Neupert's Career

Adaptive Biotechnologies
Adaptive Biotechnologies

Seattle, WA, US

Board Member· Board
Labcorp
Labcorp

Burlington, NC, US

Board Member· Board
Navigating Cancer
Navigating Cancer

Seattle, WA, US

Board Member· Board
Datavant
Datavant

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Neupert's Career

Adaptive Biotechnologies
Adaptive Biotechnologies
Public$531.9M7902009Seattle, WA, US
Board Member· Board

Leadership at Adaptive Biotechnologies

Michael PelliniMichael PelliniBoard Member
Edus WarrenEdus WarrenBoard Member
Craig WeissmanCraig WeissmanBoard Member
Robert HershbergRobert HershbergBoard Member
Christopher CarlsonChristopher CarlsonCo-Founder
Katey Einterz OwenKatey Einterz OwenBoard Member

Similar to Adaptive Biotechnologies

SeagenSeagenBothell, WA, USCancer Treatmentsest. 1997SeagenBothell, WA, US · est. 1997

Global biotech innovator developing cancer treatments.

Public · $1.7B3.3k
HI-BioHI-BioSan Francisco, CA, USBiotechest. 2021HI-BioSan Francisco, CA, US · est. 2021

HI-Bio pioneers precision medicine, targeting cellular drivers to treat immune-mediated diseases.

Series B · $215M48
Labcorp
Labcorp
Public$850M19k1971Burlington, NC, US
Board Member· Board

Leadership at Labcorp

Kirsten KliphouseKirsten KliphouseBoard Member
Jean-Luc BélingardJean-Luc BélingardBoard Member
Garheng KongGarheng KongBoard Member
Kerrii AndersonKerrii AndersonBoard Member
Adam SchechterAdam SchechterBoard Member
Richelle ParhamRichelle ParhamBoard Member

Similar to Labcorp

Quest DiagnosticsQuest DiagnosticsSecaucus, NJ, USMedical Testingest. 1967Quest DiagnosticsSecaucus, NJ, US · est. 1967

Quest Diagnostics: A national medical research company providing comprehensive diagnostic testing and services.

Public · $750M49k
Analyte HealthAnalyte HealthHouston, TX, USDiagnostics, Lab Testingest. 2010Analyte HealthHouston, TX, US · est. 2010

Analyte Health: A healthcare diagnostic partner making lab testing faster, more convenient, and accessible.

Series B · $71.8M61
LabConnectLabConnectJohnson City, TN, USLaboratory Servicesest. 2002LabConnectJohnson City, TN, US · est. 2002

Labconnect, LLC: A global provider of professional medical diagnostic and analytic services since 2002.

Series A · $28.5M556
LabQ DiagnosticsLabQ DiagnosticsNew York City, NY, USDiagnostic Testingest. 2019LabQ DiagnosticsNew York City, NY, US · est. 2019

LabQ Diagnostics: A full-service provider of automated medical diagnostic and testing solutions.

Series A · $76M600
Navigating Cancer
Navigating Cancer
Series D$55.5M852008Seattle, WA, US
Board Member· Board

Leadership at Navigating Cancer

David TraversDavid TraversBoard Member
Bill BunkerBill BunkerCEO
Gena CookGena CookCo-Founder
Eva HoEva HoCo-Founder
Michael GraffMichael GraffCo-Founder
David M RubinDavid M RubinBoard Member

Similar to Navigating Cancer

OncoHealthOncoHealthAtlanta, GA, USDigital Healthest. 2009OncoHealthAtlanta, GA, US · est. 2009

OncoHealth: A leading digital health company simplifying the complexities of cancer care.

Private Equity · $56.5M224
cancerGOcancerGOHouston, TX, USSocial Networkest. 2022cancerGOHouston, TX, US · est. 2022

CancerGO: A dedicated social network for cancer patients, survivors, and caregivers, founded in 2022.

Pre-Seed · $1M5
Smart PatientsSmart PatientsMountain View, CA, USPatient Communityest. 1995Smart PatientsMountain View, CA, US · est. 1995

Smart Patients: An online platform for cancer patients and caregivers to share experiences and learn about treatments.

Angel · $100k8
Outcomes4MeOutcomes4MeBoston, MA, USPatient Platformest. 2017Outcomes4MeBoston, MA, US · est. 2017

Outcomes4Me: An AI-driven platform empowering cancer patients with personalized, evidence-based care options.

Series A · $16.7M31
Datavant
Datavant
Series B$80.5M5412017San Francisco, CA, US
Board Member· Board

Recent news

After winning a landmark case against real estate agents, this startup aims to replace them with a flat feeTechCrunch · 2024

Leadership at Datavant

Donald BerwickDonald BerwickBoard Member
Pete McCabePete McCabeCEO
Andrew Von EschenbachAndrew Von EschenbachBoard Member
Auren HoffmanAuren HoffmanBoard Member
Abel KhoAbel KhoBoard Member
Sam NussbaumSam NussbaumBoard Member

Peter Neupert's Similar Executives & Operators

WILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · KakaoYun SeokYun SeokBoard Member · KakaoHong EuntaekHong EuntaekBoard Member · Kakao

People Similar to Peter Neupert

Chad RobinsChad RobinsCEO · Adaptive BiotechnologiesGerald NepomGerald NepomBoard Member · Adaptive BiotechnologiesHarlan RobinsHarlan RobinsCo-Founder · Adaptive BiotechnologiesPeter ThielPeter ThielFounder · Breakout LabsDaniel GutierrezDaniel GutierrezCo-Founder · Adaptyv Biosystems